Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blue Bird Corporation - Common Stock (NQ:BLBD)

33.71 +0.78 (+2.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Blue Bird Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
3 Obscure Stocks That Could Revolutionize Your Returns
Investors mostly pay close attention to popular stocks. But, there are also strong stocks with low trading volume available. 
Via InvestorPlace
Blue Bird to Report Fiscal 2024 Second Quarter Results on May 8, 2024
From Blue Bird Corporation
Via Business Wire
Deep Dive Into Blue Bird Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
Should you consider BLUE BIRD CORP (NASDAQ:BLBD) for growth investing?
Why the growth investor may take a look at BLUE BIRD CORP (NASDAQ:BLBD). 
Via Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:BLBD.
While growth is established for BLUE BIRD CORP (NASDAQ:BLBD), the stock's valuation remains reasonable. 
Via Chartmill
Ahead of the Curve: 7 Stocks to Buy Before They Go Mainstream
Discover seven overlooked stocks to buy poised for 10X returns across diverse industries. Unlock their growth potential now. 
Via InvestorPlace
Is NASDAQ:BLBD suited for growth investing?
High growth, ROE and beating expectations for NASDAQ:BLBD: growth investors may appreciate this. 
Via Chartmill
NASDAQ:BLBD, a growth stock which is not overvalued.
BLUE BIRD CORP (NASDAQ:BLBD), a growth stock which is not overvalued. 
Via Chartmill
Despite its impressive fundamentals, NASDAQ:BLBD remains undervalued.
Investors should take notice ofBLUE BIRD CORP (NASDAQ:BLBD)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
Blue Bird Corp. (NASDAQ: BLBD) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Topics Energy
Exposures Fossil Fuels
Blue Bird Corp. (NASDAQ: BLBD) Records 52-Week High Thursday Morning
Via Investor Brand Network
Topics Energy
Exposures Fossil Fuels
7 EV Stocks That Could Be Multibaggers in the Making: March Edition
Discover EV stocks poised for explosive growth, tapping into cutting-edge technology and market dominance. 
Via InvestorPlace
3 Promising Small-Cap Stocks Packing a Powerful Punch
Here're three under-the-radar small-cap stocks with robust growth potential that could deliver outsized returns for risk-tolerant investors. 
Via InvestorPlace
Is NASDAQ:BLBD a Fit for Growth Investing Strategies?
Why BLUE BIRD CORP (NASDAQ:BLBD) qualifies as a high growth stock. 
Via Chartmill
NASDAQ:BLBD is not too expensive for the growth it is showing.
BLUE BIRD CORP (NASDAQ:BLBD) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
What 4 Analyst Ratings Have To Say About Blue Bird
Via Benzinga
Beat Wall Street: 3 Stocks Flying Under the Radar
The market is full of many companies that most people haven’t even heard of. Add these stocks to your portfolio that fly under the radar. 
Via InvestorPlace
Blue Bird Corp. (NASDAQ: BLBD) Sets New 52-Week High in Friday Session
Via Investor Brand Network
Topics Energy
Exposures Fossil Fuels
7 Must-Buy Stocks for a Diversified High-Growth Portfolio
Explore how these high-growth portfolio stocks can drive substantial returns in IT, communication, industrials, and financials. 
Via InvestorPlace
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
Via Newsfile
Should you consider NASDAQ:BLBD for growth investing?
BLUE BIRD CORP (NASDAQ:BLBD) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
NASDAQ:BLBD stands out as a growth opportunity that won't break the bank.
NASDAQ:BLBD is not too expensive for the growth it is showing. 
Via Chartmill
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Wall Street Favorites: 3 EV Stocks With Strong Buy Ratings for February 2024
Though the certainty of the electric vehicle industry may be waning, these three EV stocks offer strong potential nonetheless. 
Via InvestorPlace
Topics Electric Vehicles
Exposures Electric Vehicles
3 Goliath Growth Stocks Poised for Takeoff in February
These three top-tier growth stocks to buy offer investors incredible potential returns and are perfect for long-term investing. 
Via InvestorPlace
Blue Bird Announces Launch of Secondary Public Offering
From Blue Bird Corporation
Via Business Wire
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
Via MarketBeat
Exposures Product Safety
Win-Win Situation? Nuvve's (NASDAQ: NVVE) Technology Can Potentially Turn Your Electric Vehicle Into A Revenue Stream That Helps Support The Power Grid
Electric vehicles seem poised to take over the roads, reducing global emissions and helping the world achieve a greener future. 
Via Benzinga
Topics Electric Vehicles Emissions
Exposures Electric Vehicles
Blue Bird Corp. (NASDAQ: BLBD) Records 52-Week High Thursday Morning
Via Investor Brand Network
Topics Energy
Exposures Fossil Fuels
12 Industrials Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.